San­doz to pay Al­ler­gan, Duke Uni­ver­si­ty $39M over eye drug law­suit, ju­ry says

San­doz is on the hook for $39 mil­lion to Al­ler­gan and Duke Uni­ver­si­ty for in­fring­ing on their patent for an eye­lash-growth drug, Latisse (bi­mato­prost oph­thalmic so­lu­tion), a Col­orado fed­er­al ju­ry de­cid­ed Fri­day.

In a com­plaint filed by Al­ler­gan and Duke against San­doz, Al­ler­gan said that since its launch in 2016, San­doz’s gener­ic ver­sion of Latisse has caused sales of Al­ler­gan’s prod­uct to de­cline by around 50% in Texas. Net sales for Al­ler­gan from Latisse were over $70 mil­lion an­nu­al­ly from its launch in 2009 up to 2018, when the com­plaint was filed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER